For instance, homo-combinations of antibodies against epidermal growth factor receptor (EGFR) [1,2,3,4,5], human epidermal growth factor receptor-2 (HER2) [6,7,8,9] or hepatocyte growth factor (HGF) receptor (i.e., cMET) [10,11] induce synergistic anti-tumor activity due to accelerated degradation of the targeted receptors and enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) (Figure 1). Here, EGFR is linked to neoplasm.